Multiple logistic regression analysis of baseline and on-treatment factors associated with SVR24 in Caucasian, treatment-naive, G1, noncirrhotic patients assigned to 48 weeks of treatment with PegIFN alfa-2a/RBV.

Abstract

<p>Patients who discontinued therapy for efficacy or other non-safety reasons were excluded. ^aEffect P-value: P = 0.0316 for sr-RD and 0.0001 for missed ribavirin days in percentage of target.</p